Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
Drug Toxicity: Dose-Dependent Reactions01:24

Drug Toxicity: Dose-Dependent Reactions

Drug toxicities can be stratified into pharmacological, pathological, or genotoxic based on their mechanisms. The incidence and severity of these toxicities generally increase with the drug's concentration in the body and exposure time.Pharmacological toxicity is evident when the therapeutic effects of drugs overshoot into adverse reactions in a predictable, dose-dependent manner. Central nervous system (CNS) depression from barbiturates is a classic example, with effects escalating from...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Support for new policies to regulate firearms. Results of two national surveys.

The New England journal of medicine·1998
Same author

A high-resolution linkage map of the tight skin 2 (Tsk2) locus: a mouse model for scleroderma (SSc) and other cutaneous fibrotic diseases.

Mammalian genome : official journal of the International Mammalian Genome Society·1996
Same author

Neurological complications associated with pregnancy.

British journal of anaesthesia·1995
Same author

Black-white differences in injury. Race or social class?

Annals of epidemiology·1993
Same author

Inequality, culture, and interpersonal violence.

Health affairs (Project Hope)·1993
Same author

Thalidomide for systemic lupus erythematosus.

Lancet (London, England)·1992

Related Experiment Video

Updated: May 25, 2026

Assessing Teratogenic Changes in a Zebrafish Model of Fetal Alcohol Exposure
10:07

Assessing Teratogenic Changes in a Zebrafish Model of Fetal Alcohol Exposure

Published on: March 20, 2012

Assessment of teratogenicity.

D F Hawkins1

  • 1Emeritus Professor of Obstetric Therapeutics, University of London, Hammersmith Hospital, London W12 OHS, UK.

Journal of Psychopharmacology (Oxford, England)
|February 1, 2012
PubMed
Summary
This summary is machine-generated.

Animal testing for drug teratogenicity offers limited human therapeutic value due to differing conditions and species variations. Human data from prospective surveillance and adverse reaction reports are crucial for understanding drug safety in pregnancy.

More Related Videos

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

Related Experiment Videos

Last Updated: May 25, 2026

Assessing Teratogenic Changes in a Zebrafish Model of Fetal Alcohol Exposure
10:07

Assessing Teratogenic Changes in a Zebrafish Model of Fetal Alcohol Exposure

Published on: March 20, 2012

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation
17:28

Human Pluripotent Stem Cell Based Developmental Toxicity Assays for Chemical Safety Screening and Systems Biology Data Generation

Published on: June 17, 2015

Area of Science:

  • Pharmacology
  • Toxicology
  • Reproductive Medicine

Background:

  • Animal models for drug teratogenicity testing often lack direct human relevance.
  • Discrepancies in test conditions and significant species differences limit extrapolation to human therapeutics.
  • Medicolegal and political factors frequently outweigh therapeutic significance in animal teratogenicity studies.

Purpose of the Study:

  • To critically evaluate the utility of animal testing for drug teratogenicity.
  • To identify reliable methods for assessing human teratogenic risk of drugs.
  • To highlight the importance of human surveillance data.

Main Methods:

  • Review of existing literature on animal teratogenicity testing.
  • Analysis of limitations in animal test conditions and species variability.
  • Evaluation of human data sources, including case reports, retrospective, and prospective studies.

Main Results:

  • Animal test conditions rarely mimic human therapeutic regimens.
  • Significant interspecies differences frequently complicate the interpretation of animal teratogenicity data.
  • Anecdotal case reports, while sometimes influential (e.g., thalidomide), are prone to misinformation and bias.

Conclusions:

  • Animal teratogenicity tests have limited direct relevance to human therapeutics.
  • Prospective surveillance and adverse reaction reporting in humans are the most effective methods for assessing drug teratogenicity.
  • Retrospective studies are limited by recall bias and necessitate cautious interpretation, often serving only to inform prospective research.